Paraneoplastic cerebellar degeneration: Yo-expressing tumor revealed after a 5-year follow-up with FDG-PET.

Abstract

We report a patient with anti-Yo associated paraneoplastic cerebellar degeneration (PCD) whose tumor was demonstrated 5 years after developing PCD and had strong expression of Yo (cdr2) antigen. Review of this case along with clinical series and studies of tumor growth rates question the effectiveness of the anti-tumor immune response. These studies and similar cases suggest that the tumor may trigger the anti-Yo immune response at microscopic stages of development. An overwhelming majority of anti-Yo positive patients eventually develop a detectable malignancy, which argues in favor of a poorly effective or non-sustained anti-tumor immune response.

• Authors: Rose Marie Mathew, Adam B Cohen, Steven L Galetta, Abass Alavi, Josep Dalmau
• Journal: Journal of the neurological sciences (J Neurol Sci) Vol. 250 Issue 1-2 Pg. 153-5 (Dec 01 2006) ISSN: 0022-510X [Print] Netherlands
• PMID: 17011583 (Publication Type: Case Reports, Journal Article)

Chemical References

• Biomarkers, Tumor
• CDR2 protein, human
• Nerve Tissue Proteins
• Fluorodeoxyglucose F18

Topics

• Biomarkers, Tumor (immunology)
• Breast Neoplasms (diagnostic imaging, immunology, physiopathology)
• Carcinoma (diagnostic imaging, immunology, physiopathology)
• Cerebellum (immunology, pathology, physiopathology)
• Disease Progression
• Early Diagnosis
• Female
• Fluorodeoxyglucose F18
• Follow-Up Studies
• Forecasting
• Humans
• Immunohistochemistry
• Lymph Nodes (diagnostic imaging, pathology, physiopathology)
• Middle Aged
• Neoplasm Metastasis (immunology)
• Nerve Tissue Proteins (immunology)
• Paraneoplastic Cerebellar Degeneration (immunology, physiopathology)
• Positron-Emission Tomography (standards)
• Sentinel Lymph Node Biopsy
• Time Factors